Enterprise Europe Network (Profile:BRCN20201103001)
The Chinese company is a pharmaceutical company with a number of mature drug production channels. The products cover a wide range of diseases, such as tumors, cardiovascular and cerebrovascular diseases, cardio-cerebrovascular disease, and nervous system diseases. A number of drugs are currently on various stages of clinical trials. The Chinese company plans to bring in some of the new drug projects, specifically endocrine, cardio-cerebrovascular, ocular and autoimmune diseases and tumor related drugs from the European Union via a patent license agreement or patent transfer.
With patent licensing partnership, the European company transfers the rights of R&D and sales of the selected drugs in China to the Chinese company, and the Chinese company is obliged to pay the license fee of the project in a lump sum to the European side, or pay by milestone according to different stages of the project as specified in the agreement.
The target European company should have a mature drug development team. The target innovative drug program should be Investigational New Drugs (IND) to treat endocrine, cardio-cerebrovascular, ocular and autoimmune related diseases and tumors approved in Europe by the European Medicines Agency (EMA) or in the United States by the Food and Drug Administration (FDA ), with pharmacodynamics, pharmacokinetics, and safety evaluation.
For more information please contact Enterprise Europe Network Latvia.